These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

723 related articles for article (PubMed ID: 29176657)

  • 41. Combination therapy in dyslipidemia: where are we now?
    Catapano AL; Farnier M; Foody JM; Toth PP; Tomassini JE; Brudi P; Tershakovec AM
    Atherosclerosis; 2014 Nov; 237(1):319-35. PubMed ID: 25299967
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dyslipidemia and nephrotic syndrome: recent advances.
    Kronenberg F
    J Ren Nutr; 2005 Apr; 15(2):195-203. PubMed ID: 15827892
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lipid-Lowering Therapies for Atherosclerosis: Statins, Fibrates, Ezetimibe and PCSK9 Monoclonal Antibodies.
    Ali AH; Younis N; Abdallah R; Shaer F; Dakroub A; Ayoub MA; Iratni R; Yassine HM; Zibara K; Orekhov A; El-Yazbi AF; Eid AH
    Curr Med Chem; 2021; 28(36):7427-7445. PubMed ID: 33655822
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
    Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease.
    Mathew RO; Rosenson RS; Lyubarova R; Chaudhry R; Costa SP; Bangalore S; Sidhu MS
    Cardiovasc Drugs Ther; 2021 Jun; 35(3):479-489. PubMed ID: 32556851
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Hyperlipoproteinemia and dyslipidemia as rare diseases. Diagnostics and treatment].
    Češka R; Štulc T; Votavová L; Schwarzová L; Vaclová M; Freiberger T
    Vnitr Lek; 2016; 62(11):887-894. PubMed ID: 28128575
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Advances in the management of dyslipidemia.
    Kampangkaew J; Pickett S; Nambi V
    Curr Opin Cardiol; 2017 Jul; 32(4):348-355. PubMed ID: 28505047
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
    Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
    Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lipid-lowering treatment in peripheral artery disease.
    Katsiki N; Giannoukas AD; Athyros VG; Mikhailidis DP
    Curr Opin Pharmacol; 2018 Apr; 39():19-26. PubMed ID: 29413998
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evolving concepts on benefits and risks associated with therapeutic strategies to raise HDL.
    Shah PK
    Curr Opin Cardiol; 2010 Nov; 25(6):603-8. PubMed ID: 20827180
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antilipidemic Drug Therapy Today and in the Future.
    Kramer W
    Handb Exp Pharmacol; 2016; 233():373-435. PubMed ID: 26330256
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Management of hypercholesterolaemia in postmenopausal women.
    Davidson MH; Maki KC; Karp SK; Ingram KA
    Drugs Aging; 2002; 19(3):169-78. PubMed ID: 12027776
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HDL-Targeting Therapeutics: Past, Present and Future.
    Zakiev E; Feng M; Sukhorukov V; Kontush A
    Curr Pharm Des; 2017; 23(8):1207-1215. PubMed ID: 27799042
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Management of dyslipidaemias in the elderly population-A narrative review.
    Anagnostis P; Vaitsi K; Veneti S; Georgiou T; Paschou SA; Lambrinoudaki I; Goulis DG
    Maturitas; 2019 Jun; 124():93-99. PubMed ID: 30910278
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting.
    Zheng-Lin B; Ortiz A
    Drugs; 2018 Feb; 78(2):215-229. PubMed ID: 29299849
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Choosing the right lipid-regulating agent. A guide to selection.
    Farmer JA; Gotto AM
    Drugs; 1996 Nov; 52(5):649-61. PubMed ID: 9118815
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lipid parameters, lipid lowering drugs and the risk of venous thromboembolism.
    Delluc A; Malécot JM; Kerspern H; Nowak E; Carre JL; Mottier D; Le Gal G; Lacut K
    Atherosclerosis; 2012 Jan; 220(1):184-8. PubMed ID: 22035572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.